Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Personal Microarray Solution

September 9, 2010 12:15 pm | Drug Discovery & Development | Product Releases | Comments

Affymetrix has launched the GeneAtlas System, which offers a complete personal solution for processing Affymetrix microarrays including stations for fluidics, imaging and hybridization, a computer workstation, and analysis software.

TOPICS:

Colony Formation Assay

September 9, 2010 8:48 am | Product Releases | Comments

TTP LabTech has validated a new cell colony formation assay on the Acumen eX3 fluorescence microplate cytometer in collaboration with ChemPartner.

TOPICS:

ISCA-UPD Array

September 9, 2010 8:44 am | Product Releases | Comments

Oxford Gene Technology (OGT), provider of clinical genetics and diagnostic solutions to advance molecular medicine, has introduced the CytoSure ISCA UPD 4 x 180k array.

TOPICS:
Advertisement

Cetero Launches Scientific Seminars

September 9, 2010 8:27 am | News | Comments

Cetero Research is launching a series of scientific seminars, “An Accelerated Path to Proof-of-Concept in Drug Development,” designed to help pharmaceutical and biotechnology researchers learn the latest innovations in Phase 1 and 2a clinical trial designs.

TOPICS:

Ambry Genetics Becomes First CSP for SeqCap EZ Exome

September 9, 2010 8:18 am | News | Comments

Roche NimbleGen announces that Southern California-based genomic services provider Ambry Genetics has officially become a Certified Service Provider for the NimbleGen SeqCap EZ Exome workflow.

TOPICS:

Protein Protects Against Arthritis

September 9, 2010 8:01 am | News | Comments

Elimination of a molecular gatekeeper leads to the development of arthritis in mice, scientists report. The newly discovered gatekeeper is a protein that determines the fate of damaging cells that mistakenly attack the body's own tissues and lead to autoimmune disorders.

TOPICS:

Microbial Sex and Virulence Linked

September 9, 2010 7:58 am | News | Comments

Two opportunistic pathogens that were once thought to be very different have evolved some sexual reproduction and disease-causing habits that are not only similar but also suggest that in the microbial world sex and virulence are closely linked.

TOPICS:

Cachexia Found to Affect Heart Muscle

September 9, 2010 7:52 am | News | Comments

The wasting disease associated with some cancers that is typically seen affecting skeletal muscles can also cause significant damage to the heart, new research in mice suggests.

TOPICS:
Advertisement

New Memory Gene Identified

September 9, 2010 7:49 am | News | Comments

A team of researchers has for the first time identified a gene that is required for memory formation in the common fruit fly. The gene may have similar functions in humans shedding light on neurological disorders such as Alzheimer's disease.

TOPICS:

PolyTherics And DSM In Manufacture Agreement

September 9, 2010 7:36 am | News | Comments

DSM BioSolutions and PolyTherics Limited, an innovator in precision engineering of proteins, announced that they have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG IFN ?-2a.

TOPICS:

Seaside Study Shows Improvement in Irritability in ASD

September 9, 2010 6:56 am | News | Comments

Seaside Therapeutics, Inc. announced positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD).

TOPICS:

IMP321 Achieves Benefit in MBC Patients

September 9, 2010 6:52 am | News | Comments

Immutep S.A. announced the publication of a clinical research paper showing that its lead product, IMP321, given with first-line paclitaxel achieved clinical benefit in 90% of metastatic breast carcinoma patients.

TOPICS:

Telaprevir Achieves 65% SVR in REALIZE Study

September 9, 2010 6:46 am | News | Comments

Vertex Pharmaceuticals Incorporated announced that 65% of people overall achieved a sustained viral response (viral cure) with a telaprevir-based regimen in the Phase 3 REALIZE study, compared to 17% of people who received pegylated-interferon and ribavirin alone.

TOPICS:

Woman Receives $21M In Side Effect Suit

September 9, 2010 6:30 am | by Lynne Tuohy | News | Comments

A federal jury in New Hampshire has awarded $21 million to a woman blinded and scarred by a prescription drug she took for shoulder pain.

TOPICS:

Emergent's Trubion Buyout Given All-Clear

September 9, 2010 6:27 am | News | Comments

The planned buyout of Trubion Pharmaceuticals Inc. by Emergent BioSolutions Inc. cleared a regulatory hurdle, bringing the deal, potentially worth $135.5 million, closer to closing.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading